RemeGen's H1 Revenue Surges 433%; China's Drug Administration Strengthens Policy Support for Traditional Chinese Medicine
nashnova research
RemeGen (09995) posted H1 2026 revenue of RMB 5.85 billion, up 433% year-on-year, swinging to a net profit of RMB 4.66 billion from a loss — driven by a wave of out-licensing cash; the same day, China's drug regulator signaled looser approvals for traditional Chinese medicine, both pointing to an accelerating commercialization cycle for Chinese innovative drugs.
Why did revenue quadruple?
The core driver is out-licensing income hitting the books at once: in January 2026, RemeGen signed an exclusive license with AbbVie for RC148, collecting a $650 million upfront payment plus up to $4.95 billion in milestone payments.
This means → the jump is not from selling more drugs at the pharmacy counter — it is a one-time, lump-sum licensing fee recognized in H1, pushing revenue from RMB 1.10 billion to RMB 5.85 billion.
In plain terms = RemeGen sold the global rights to a drug it developed, pocketed a large signing fee upfront, and stands to earn more if the drug sells well overseas.
How did losses turn into profit overnight?
Net loss was RMB 450 million in H1 2025; net profit hit RMB 4.66 billion in H1 2026 — a full swing to black.
This means → virtually all of the profit came from licensing income, which carries an extremely high margin because it requires no additional manufacturing or sales cost.
Four core drugs have now been fully licensed globally, with cumulative deal value exceeding $12.6 billion — a sign of strong market confidence in RemeGen's pipeline.
How are its own products selling?
Telitacicept has been approved for five indications and was added to the National Essential Medicines List in July 2026. This means → hospitals must now stock it as a priority, significantly widening patient access.
Disitamab vedotin — a targeted cancer antibody-drug conjugate — added two new indications this year, broadening its commercial reach.
In plain terms = licensing fees are a one-shot windfall; product sales scaling up is what underpins long-term revenue.
What signal did the drug regulator send the same day?
China's National Medical Products Administration (NMPA) held a symposium on traditional Chinese medicine (TCM) regulation, consulting academicians and senior TCM experts, and pledged to strengthen policy support for the TCM sector.
Specific directions include: streamlining the review and approval process, facilitating conversion of proven classical formulas and hospital preparations into registered new drugs, and broadening natural-drug R&D pathways.
This means → the regulator is widening the pathway from "time-tested recipe" to "officially approved new drug," lowering the bar for TCM innovation to reach the market.
What does this mean for investors?
RemeGen's blowout results validate a playbook: R&D-strong biotechs can monetize fast through global out-licensing, without waiting for slow drug-sales ramp-ups.
If TCM approval reforms materialize, the valuation framework for the TCM innovative-drug space could be repriced — but whether policy can meaningfully speed up new-drug launches remains the key uncertainty.
In plain terms = one story is about cashing in on IP, the other about lowering regulatory hurdles — both point to faster commercialization of Chinese innovative drugs, but sustainability still needs watching.
市场有风险，内容仅供研究参考，不构成投资建议。